277 results on '"Bochner BS"'
Search Results
2. Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro
- Author
-
Matsumoto, K, primary, Schleimer, RP, additional, Saito, H, additional, Iikura, Y, additional, and Bochner, BS, additional
- Published
- 1995
- Full Text
- View/download PDF
3. The role of lung epithelial ligands for Siglec-8 and Siglec-F in eosinophilic inflammation.
- Author
-
Kiwamoto T, Katoh T, Tiemeyer M, Bochner BS, Kiwamoto, Takumi, Katoh, Toshihiko, Tiemeyer, Michael, and Bochner, Bruce S
- Published
- 2013
- Full Text
- View/download PDF
4. Expression of a functional laminin receptor (alpha 6 beta 1, very late activation antigen-6) on human eosinophils
- Author
-
Georas, SN, primary, McIntyre, BW, additional, Ebisawa, M, additional, Bednarczyk, JL, additional, Sterbinsky, SA, additional, Schleimer, RP, additional, and Bochner, BS, additional
- Published
- 1993
- Full Text
- View/download PDF
5. Adhesion molecule antagonists: future therapies for allergic diseases?
- Author
-
Wein, M, primary and Bochner, BS, additional
- Published
- 1993
- Full Text
- View/download PDF
6. Immunophenotyping and functional analysis of purified human uterine mast cells
- Author
-
Guo, CB, primary, Kagey-Sobotka, A, additional, Lichtenstein, LM, additional, and Bochner, BS, additional
- Published
- 1992
- Full Text
- View/download PDF
7. Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.
- Author
-
Khoury P, Roufosse F, Kuang FL, Ackerman SJ, Akuthota P, Bochner BS, Johansson MW, Mathur SK, Ogbogu PU, Spencer LA, Wechsler ME, Zimmermann N, and Klion AD
- Subjects
- Humans, Biological Therapy methods, Rare Diseases drug therapy, Rare Diseases therapy, Eosinophilia drug therapy, Hypereosinophilic Syndrome drug therapy, Hypereosinophilic Syndrome therapy, Translational Research, Biomedical, Eosinophils immunology
- Abstract
Rare eosinophil-associated disorders (EADs), including hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, and eosinophilic gastrointestinal disorders, are a heterogeneous group of conditions characterized by blood and/or tissue hypereosinophilia and eosinophil-related clinical manifestations. Although the recent availability of biologic therapies that directly and indirectly target eosinophils has the potential to dramatically improve treatment options for all EADs, clinical trials addressing their safety and efficacy in rare EADs have been relatively few. Consequently, patient access to therapy is limited for many biologics, and the establishment of evidence-based treatment guidelines has been extremely difficult. In this regard, multicenter retrospective collaborative studies focusing on disease manifestations and treatment responses in rare EADs have provided invaluable data for physicians managing patients with these conditions and helped identify important questions for future translational research. During the Clinical Pre-Meeting Workshop held in association with the July 2023 biennial meeting of the International Eosinophil Society in Hamilton, Ontario, Canada, the successes and limitations of pivotal multicenter retrospective studies in EADs were summarized and unmet needs regarding the establishment of guidelines for use of biologics in rare EADs were discussed. Key topics of interest included (1) clinical outcome measures, (2) minimally invasive biomarkers of disease activity, (3) predictors of response to biologic agents, and (4) long-term safety of eosinophil depletion. Herein, we report a summary of these discussions, presenting a state-of-the-art overview of data currently available for each of these topics, the limitations of the data, and avenues for future data generation through implementation of multidisciplinary and multicenter studies., Competing Interests: Conflict of interest statement. F.R. receives consultancy and/or speaker fees from GlaxoSmithKline, AstraZeneca, Menarini, and Merck. F.L.K. receives research funding from AstraZeneca and speaker fees from both AstraZeneca and GlaxoSmithKline. S.J.A. is the Chief Scientific Officer and an Executive Board member of EnteroTrack, LLC; a co-inventor and holds patents on the Esophageal String Test; and a consultant for Areteia Pharmaceuticals. P.A. has received consulting fees and research support from AstraZeneca, GlaxoSmithKline, and Sanofi and research support from Regeneron. B.S.B. receives remuneration for serving on the scientific advisory board of Allakos, Inc.; owns stock in Allakos; currently serves as a consultant for Third Harmonic Bio and Sanofi/Regeneron; receives publication-related royalty payments from Elsevier and UpToDate; is a co-inventor on existing Siglec-8–related patents and thus may be entitled to a share of royalties received by Johns Hopkins University during development and potential sales of such products; and is a co-founder of Allakos, which makes him subject to certain restrictions under university policy (the terms of this arrangement are being managed by Johns Hopkins University and Northwestern University in accordance with their conflict-of-interest policies). M.W.J. has received research funding from F. Hoffmann-La Roche. S.K.M. has received consulting, advisory, or speaking honoraria from AstraZeneca, Amgen, GlaxoSmithKline, Novartis, and Sanofi/Regeneron. P.O.B. receives research funding from GlaxoSmithKline, AstraZeneca, Blueprint, and DBV Technologies; and serves on advisory boards for AstraZeneca, Sanofi, Genentech, and Kalvista. M.E.W. has received consulting, advisory, or speaking honoraria from Amgen, Areteia Therapeutics, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Celldex, Cellergy Pharma, Cerecor, Cytoreason, Eli Lilly, Equillium, Glaxosmithkline, Incyte, Kinaset, Merck, Novartis, Om Pharma, Overtone Therapeutics/Foresite Labs, Phylaxis, Pulmatrix, Rapt Therapeutics, Regeneron, Roche/Genentech, Sanofi/Genzyme, Sentien, Sound Biologics, Tetherex Pharmaceuticals, Teva, Upstream Bio, and Verona Pharma. The other authors have no conflicts of interest to disclose., (Published by Oxford University Press on behalf of Society for Leukocyte Biology 2024.)
- Published
- 2024
- Full Text
- View/download PDF
8. Prevention of allergic reactions during oxaliplatin desensitization through inhibition of Bruton tyrosine kinase.
- Author
-
Erickson KA, Norton JE, Law J, Soriano N, Strojny M, Gentry N, Fried M, Bochner BS, Kircher S, and Stevens WW
- Subjects
- Humans, Middle Aged, Male, Anaphylaxis prevention & control, Anaphylaxis chemically induced, Anaphylaxis immunology, Stomach Neoplasms drug therapy, Stomach Neoplasms immunology, Oxaliplatin adverse effects, Drug Hypersensitivity immunology, Drug Hypersensitivity prevention & control, Desensitization, Immunologic methods, Agammaglobulinaemia Tyrosine Kinase antagonists & inhibitors, Pyrazines adverse effects, Pyrazines administration & dosage, Pyrazines therapeutic use, Benzamides therapeutic use, Benzamides administration & dosage, Antineoplastic Agents adverse effects
- Abstract
Background: Acute infusion reactions to oxaliplatin, a chemotherapeutic used to treat gastrointestinal cancers, are observed in about 20% of patients. Rapid drug desensitization (RDD) protocols often allow the continuation of oxaliplatin in patients with no alternative options. Breakthrough symptoms, including anaphylaxis, can still occur during RDD., Objective: Our aim was to evaluate whether pretreatment with acalabrutinib, a Bruton tyrosine kinase inhibitor, can prevent anaphylaxis during RDD in a patient sensitized to oxaliplatin., Methods: A 52-year-old male with locally advanced gastric carcinoma developed anaphylaxis during his fifth cycle of oxaliplatin. As he required 6 additional cycles to complete his curative-intent treatment regimen, he underwent RDD to oxaliplatin but still developed severe acute reactions. The risks and benefits of adding acalabrutinib before and during RDD were reviewed, and the patient elected to proceed., Results: With acalabrutinib taken before and during the RDD, the patient was able to tolerate oxaliplatin RDD without complication. Consistent with its mechanism of action, acalabrutinib completely blocked the patient's positive skin prick response to oxaliplatin. Acalabrutinib did not alter the percentage of circulating basophils (1.24% vs 0.98%) before the RDD but did protect against basopenia (0.74% vs 0.09%) after the RDD. Acalabrutinib was associated with a drastic reduction in the ability of basophils to upregulate CD63 in vitro following incubation with oxaliplatin (0.11% vs 2.38%) or polyclonal anti-human IgE antibody (0.08% vs 44.2%)., Conclusions: Five doses of acalabrutinib, 100 mg, orally twice daily starting during the evening 2 days before and continuing through RDD allowed a sensitized patient to receive oxaliplatin successfully and safely., (Copyright © 2024 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. scRNA-seq profiling of human granulocytes reveals expansion of developmentally flexible neutrophil precursors with mixed neutrophil and eosinophil properties in asthma.
- Author
-
Haruna NF, Politanska Y, Connelly AR, O'Connor K, Bhattacharya S, Miklaszewski GE, Pérez-Leonor XG, Rerko G, Hentenaar IT, Nguyen DC, Lamothe Molina PA, Bochner BS, Abdala-Valencia H, Gill MA, Lee FE, and Berdnikovs S
- Abstract
Neutrophils and eosinophils share common hematopoietic precursors and usually diverge into distinct lineages with unique markers before being released from their hematopoietic site, which is the bone marrow (BM). However, previous studies identified an immature Ly6g(+) Il-5Rα(+) neutrophil population in mouse BM, expressing both neutrophil and eosinophil markers suggesting hematopoietic flexibility. Moreover, others have reported neutrophil populations expressing eosinophil-specific cell surface markers in tissues and altered disease states, confusing the field regarding eosinophil origins, function, and classification. Despite these reports, it is still unclear whether hematopoietic flexibility exists in human granulocytes. To answer this, we utilized single-cell RNA sequencing (scRNA-seq) and CITE-seq to profile human BM and circulating neutrophils and eosinophils at different stages of differentiation and determine whether neutrophil plasticity plays role in asthmatic inflammation. We show that immature metamyelocyte neutrophils in humans expand during severe asthmatic inflammation and express both neutrophil and eosinophil markers. We also show an increase in tri-lobed eosinophils with mixed neutrophil and eosinophil markers in allergic asthma and that IL-5 promotes differentiation of immature blood neutrophils into tri-lobed eosinophilic phenotypes suggesting a mechanism of emergency granulopoiesis to promote myeloid inflammatory or remodeling response in patients with chronic asthma. By providing insights into unexpectedly flexible granulocyte biology and demonstrating emergency hematopoiesis in asthma, our results highlight the importance of granulocyte plasticity in eosinophil development and allergic diseases., (© The Author(s) 2024. Published by Oxford University Press on behalf of Society for Leukocyte Biology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
10. Single cell RNA sequencing of human eosinophils from nasal polyps reveals eosinophil heterogeneity in chronic rhinosinusitis tissue.
- Author
-
Iwasaki N, Poposki JA, Oka A, Kidoguchi M, Klingler AI, Suh LA, Bai J, Stevens WW, Peters AT, Grammer LC, Welch KC, Smith SS, Conley DB, Schleimer RP, Kern RC, Bochner BS, Tan BK, and Kato A
- Abstract
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by type 2 inflammation in the United States, but the actual roles that eosinophils play in CRSwNP remain largely unclear., Objective: To reveal the roles and heterogeneity of eosinophils in nasal polyp (NP) tissue, we performed single cell RNA sequencing (scRNA-Seq) analysis of NP tissue., Methods: Sinonasal tissues (NP and control sinus tissue) and patient matched peripheral blood (PB) samples were obtained from 5 control patients and 5 patients with CRSwNP. Eosinophils were enriched before processing for scRNA-Seq. The gene expression profiles in eosinophils were determined by microwell-based scRNA-Seq technology (BD Rhapsody platform). We predicted the overall function of NP eosinophils by Gene Ontology (geneontology.org) enrichment and pathway analyses and confirmed expression of selected genes by flow cytometry., Results: After filtering out contaminating cells, we detected 5,542 eosinophils from control PB, 3,883 eosinophils from CRSwNP PB, 101 eosinophils from control sinus tissues (not included in further analyses), and 9,727 eosinophils from NPs by scRNA-Seq. We found that 204 genes were downregulated and 354 genes upregulated in NP eosinophils compared to all PB eosinophils (>1.5-fold, P
adj < .05). Upregulated genes in NP eosinophils were associated with activation, cytokine-mediated signaling, growth factor activity, NF-κB signaling, and antiapoptotic molecules. NP eosinophils displayed 4 clusters revealing potential heterogeneity of eosinophils in NP tissue., Conclusions: Elevated eosinophils in NP tissue appear to exist in several subtypes that may play important pathogenic roles in CRSwNP, in part by controlling inflammation and hyperproliferation of other cells., Competing Interests: Disclosure statement Supported in part by Regeneron Pharmaceuticals, the National Institutes of Health (grants P01AI145818, R01AI137174, and U19AI136443), and a grant from the Ernest S. Bazley Foundation. Disclosure of potential conflict of interest: W. W. Stevens has served on advisory boards for GlaxoSmithKline, Regeneron, and Melinta Therapeutics. A. T. Petershas served on advisory boards for Sanofi-Genzyme/Regeneron, Optinose, AstraZeneca, Novartis, and GSK; and has received research support from Optinose and Sanofi/Regeneron. L. C. Grammer reports personal fees from Astellas Pharmaceuticals. K. C. Welch reports consultant fees from Baxter, OptiNose, and Acclarent. D. B. Conley reports consulting fees from Medtronic and Sanofi/Regeneron. R. P. Schleimer reports personal fees from Intersect ENT, Merck, GlaxoSmithKline, Sanofi, AstraZeneca/Medimmune, Genentech, Actobio Therapeutics, Lyra Therapeutics, Astellas Pharma, and Otsuka; and has royalty rights to Siglec-8 and Siglec-8 ligand–related patents licensed by Johns Hopkins to Allakos. R. C. Kern reports consulting fees from Lyra Therapeutics, Medtronic, GSK, Genentech and Sanofi/Regeneron. B. S. Bochner has received remuneration for serving on scientific advisory board of Allakos and owns stock in Allakos; has served as consultant for GSK, Third Harmonic Bio, Lupagen, Acelyrin, and Sanofi/Regeneron; receives publication-related royalty payments from Elsevier and UpToDate; is coinventor of existing Siglec-8–related patents and thus may be entitled to a share of royalties received by Johns Hopkins University during development and potential sales of such products; and is a cofounder of Allakos, which makes him subject to certain restrictions under university policy (terms of this arrangement are being managed by Johns Hopkins University and Northwestern University in accordance with their conflict-of-interest policies). B. K. Tan reports personal fees from Sanofi/Regeneron/Genzyme and GSK. A. Kato has served on advisory board for AstraZeneca; reports gift for his research from Lyra Therapeutics; and has received research grants from Regeneron and AstraZeneca. The rest of the authors declare that they have no relevant conflicts of interest., (Copyright © 2024 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
11. Controlled adsorption of multiple bioactive proteins enables targeted mast cell nanotherapy.
- Author
-
Du F, Rische CH, Li Y, Vincent MP, Krier-Burris RA, Qian Y, Yuk SA, Almunif S, Bochner BS, Qiao B, and Scott EA
- Subjects
- Animals, Mice, Adsorption, Humans, Nanomedicine methods, Anaphylaxis, Polypropylenes chemistry, Cell Degranulation drug effects, Mast Cells drug effects, Mast Cells metabolism, Nanoparticles chemistry
- Abstract
Protein adsorption onto nanomaterials often results in denaturation and loss of bioactivity. Controlling the adsorption process to maintain the protein structure and function has potential for a range of applications. Here we report that self-assembled poly(propylene sulfone) (PPSU) nanoparticles support the controlled formation of multicomponent enzyme and antibody coatings and maintain their bioactivity. Simulations indicate that hydrophobic patches on protein surfaces induce a site-specific dipole relaxation of PPSU assemblies to non-covalently anchor the proteins without disrupting the protein hydrogen bonding or structure. As a proof of concept, a nanotherapy employing multiple mast-cell-targeted antibodies for preventing anaphylaxis is demonstrated in a humanized mouse model. PPSU nanoparticles displaying an optimized ratio of co-adsorbed anti-Siglec-6 and anti-FcεRIα antibodies effectively inhibit mast cell activation and degranulation, preventing anaphylaxis. Protein immobilization on PPSU surfaces provides a simple and rapid platform for the development of targeted protein nanomedicines., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
12. Little to no mRNA for the α- or β-chains of FcεRI in human eosinophils.
- Author
-
Chhiba KD, Kuang FL, Berdnikovs S, Kato A, and Bochner BS
- Subjects
- Humans, RNA, Messenger genetics, Receptors, IgE genetics, Eosinophils, Immunoglobulin E
- Published
- 2024
- Full Text
- View/download PDF
13. Interactions between Siglec-8 and endogenous sialylated cis ligands restrain cell death induction in human eosinophils and mast cells.
- Author
-
Cao Y, Rische CH, Bochner BS, and O'Sullivan JA
- Subjects
- Humans, Ligands, Reactive Oxygen Species metabolism, Interleukin-5 metabolism, Antigens, CD metabolism, Cell Death, Sialic Acid Binding Immunoglobulin-like Lectins metabolism, Cytokines metabolism, Eosinophils, Mast Cells
- Abstract
Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is a sialoside-binding receptor expressed by eosinophils and mast cells that exhibits priming status- and cell type-dependent inhibitory activity. On eosinophils that have been primed with IL-5, GM-CSF, or IL-33, antibody ligation of Siglec-8 induces cell death through a pathway involving the β2 integrin-dependent generation of reactive oxygen species (ROS) via NADPH oxidase. In contrast, Siglec-8 engagement on mast cells inhibits cellular activation and mediator release but reportedly does not impact cell viability. The differences in responses between cytokine-primed and unprimed eosinophils, and between eosinophils and mast cells, to Siglec-8 ligation are not understood. We previously found that Siglec-8 binds to sialylated ligands present on the surface of the same cell (so-called cis ligands), preventing Siglec-8 ligand binding in trans. However, the functional relevance of these cis ligands has not been elucidated. We therefore explored the potential influence of cis ligands of Siglec-8 on both eosinophils and mast cells. De-sialylation using exogenous sialidase profoundly altered the consequences of Siglec-8 antibody engagement on both cell types, eliminating the need for cytokine priming of eosinophils to facilitate cell death and enabling Siglec-8-dependent mast cell death without impacting anti-Siglec-8 antibody binding. The cell death process licensed by de-sialylation resembled that characterized in IL-5-primed eosinophils, including CD11b upregulation, ROS production, and the activities of Syk, PI3K, and PLC. These results implicate cis ligands in restraining Siglec-8 function on eosinophils and mast cells and reveal a promising approach to the selective depletion of mast cells in patients with mast cell-mediated diseases., Competing Interests: Author BB receives remuneration for serving on the scientific advisory board of Allakos, Inc. and owns stock in Allakos. He has served as a consultant for GSK, Third Harmonic Bio, Lupagen, Acelyrin, and Sanofi/Regeneron, and receives publication-related royalty payments from Elsevier and UpToDate®. He is a co-inventor on existing Siglec-8–related patents and thus may be entitled to a share of royalties received by Johns Hopkins University during development and potential sales of such products. Author BB is also a co-founder of Allakos, which makes him subject to certain restrictions under University policy. The terms of this arrangement are being managed by Johns Hopkins University and Northwestern University in accordance with their conflict of interest policies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Cao, Rische, Bochner and O’Sullivan.)
- Published
- 2023
- Full Text
- View/download PDF
14. Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases.
- Author
-
O'Sullivan JA, Youngblood BA, Schleimer RP, and Bochner BS
- Subjects
- Humans, Mast Cells, Antigens, CD chemistry, Ligands, Sialic Acid Binding Immunoglobulin-like Lectins metabolism, Eosinophils
- Abstract
Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of vertebrate glycan-binding cell-surface proteins. The majority mediate cellular inhibitory activity once engaged by specific ligands or ligand-mimicking molecules. As a result, Siglec engagement is now of interest as a strategy to therapeutically dampen unwanted cellular responses. When considering allergic inflammation, human eosinophils and mast cells express overlapping but distinct patterns of Siglecs. For example, Siglec-6 is selectively and prominently expressed on mast cells while Siglec-8 is highly specific for both eosinophils and mast cells. This review will focus on a subset of Siglecs and their various endogenous or synthetic sialoside ligands that regulate eosinophil and mast cell function and survival. It will also summarize how certain Siglecs have become the focus of novel therapies for allergic and other eosinophil- and mast cell-related diseases., Competing Interests: Conflict of interest statement J.A.O. has nothing to disclose. B.A.Y. is a current employee of, and owns stock and stock options from, Allakos, Inc. R.P.S. received consulting fees from Intersect ENT, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, Medimmune, Genentech, Actobio Therapeutics, Lyra Therapeutics, Astellas Pharma, Allakos and Otsuka. He also receives royalties from Siglec-8 and Siglec-8 ligand related patents licensed by Johns Hopkins University to Allakos, Inc. and owns stock in Allakos. B.S.B. receives remuneration for serving on the scientific advisory board of Allakos, Inc. and owns stock in Allakos. He receives consulting fees from Third Harmonic Bio, Lupagen, Sanofi, and Acelyrin. He receives publication-related royalty payments from Elsevier and UpToDate. He is a co-inventor on existing Siglec-8–related patents and thus may be entitled to a share of royalties received by Johns Hopkins University during development and potential sales of such products. B.S.B. is also a co-founder of Allakos, Inc. which makes him subject to certain restrictions under university policy. The terms of this arrangement are being managed by Johns Hopkins University and Northwestern University in accordance with their conflict-of-interest policies., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
15. A Cell-Free Protein Synthesis Platform to Produce a Clinically Relevant Allergen Panel.
- Author
-
Thames AH, Rische CH, Cao Y, Krier-Burris RA, Kuang FL, Hamilton RG, Bronzert C, Bochner BS, and Jewett MC
- Subjects
- Humans, Phylogeny, Allergens, Immunoglobulin E
- Abstract
Allergens are used in the clinical diagnosis (e.g., skin tests) and treatment (e.g., immunotherapy) of allergic diseases. With growing interest in molecular allergy diagnostics and precision therapies, new tools are needed for producing allergen-based reagents. As a step to address this need, we demonstrate a cell-free protein synthesis approach for allergen production of a clinically relevant allergen panel composed of common allergens spanning a wide range of phylogenetic kingdoms. We show that allergens produced with this approach can be recognized by allergen-specific immunoglobulin E (IgE), either monoclonals or in patient sera. We also show that a cell-free expressed allergen can activate human cells such as peripheral blood basophils and CD34+ progenitor-derived mast cells in an IgE-dependent manner. We anticipate that this cell-free platform for allergen production will enable diagnostic and therapeutic technologies, providing useful tools and treatments for both the allergist and allergic patient.
- Published
- 2023
- Full Text
- View/download PDF
16. A phase II study of Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis.
- Author
-
Suresh RV, Dunnam C, Vaidya D, Wood RA, Bochner BS, MacGlashan DW Jr, and Dispenza MC
- Subjects
- Adult, Humans, Agammaglobulinaemia Tyrosine Kinase, Benzamides pharmacology, Pyrazines adverse effects, Allergens, Arachis, Anaphylaxis prevention & control, Peanut Hypersensitivity drug therapy, Peanut Hypersensitivity prevention & control
- Abstract
BACKGROUNDIgE-mediated anaphylaxis is a potentially fatal systemic allergic reaction for which there are no currently FDA-approved preventative therapies. Bruton's tyrosine kinase (BTK) is an essential enzyme for IgE-mediated signaling pathways and is an ideal pharmacologic target to prevent allergic reactions. In this open-label trial, we evaluated the safety and efficacy of acalabrutinib, a BTK inhibitor that is FDA approved to treat some B cell malignancies, in preventing clinical reactivity to peanut in adults with peanut allergy.METHODSAfter undergoing graded oral peanut challenge to establish their baseline level of clinical reactivity, 10 patients had a 6-week rest period, then received 4 standard doses of 100 mg acalabrutinib twice daily and underwent repeat food challenge. The primary endpoint was the change in patients' threshold dose of peanut protein to elicit an objective clinical reaction.RESULTSAt baseline, patients tolerated a median of 29 mg of peanut protein before objective clinical reaction. During subsequent food challenge on acalabrutinib, patients' median tolerated dose significantly increased to 4,044 mg (range 444-4,044 mg). 7 patients tolerated the maximum protocol amount (4,044 mg) of peanut protein with no clinical reaction, and the other 3 patients' peanut tolerance increased between 32- and 217-fold. 3 patients experienced a total of 4 adverse events that were considered to be possibly related to acalabrutinib; all events were transient and nonserious.CONCLUSIONAcalabrutinib pretreatment achieved clinically relevant increases in patients' tolerance to their food allergen, thereby supporting the need for larger, placebo-controlled trials.TRIAL REGISTRATIONClinicalTrials.gov NCT05038904FUNDINGAstraZeneca Pharmaceuticals, the Johns Hopkins Institute for Clinical and Translational Research, the Ludwig Family Foundation, and NIH grants AI143965 and AI106043.
- Published
- 2023
- Full Text
- View/download PDF
17. GlycoCAP: A Cell-Free, Bacterial Glycosylation Platform for Building Clickable Azido-Sialoglycoproteins.
- Author
-
Thames AH, Moons SJ, Wong DA, Boltje TJ, Bochner BS, and Jewett MC
- Subjects
- Glycosylation, Lectins metabolism, Polysaccharides metabolism, Cell-Free System, Glycoproteins, Sialoglycoproteins metabolism
- Abstract
Glycan-binding receptors known as lectins represent a class of potential therapeutic targets. Yet, the therapeutic potential of targeting lectins remains largely untapped due in part to limitations in tools for building glycan-based drugs. One group of desirable structures is proteins with noncanonical glycans. Cell-free protein synthesis systems have matured as a promising approach for making glycoproteins that may overcome current limitations and enable new glycoprotein medicines. Yet, this approach has not been applied to the construction of proteins with noncanonical glycans. To address this limitation, we develop a cell-free glycoprotein synthesis platform for building noncanonical glycans and, specifically, clickable azido-sialoglycoproteins (called GlycoCAP). The GlycoCAP platform uses an Escherichia coli -based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency. As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose. Through a series of optimizations, we achieve more than 60% sialylation efficiency with a noncanonical azido-sialic acid. We then show that the azide click handle can be conjugated with a model fluorophore using both strain-promoted and copper-catalyzed click chemistry. We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
- Published
- 2023
- Full Text
- View/download PDF
18. Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis: an open-label, phase 2 trial.
- Author
-
Suresh RV, Dunnam C, Vaidya D, Wood RA, Bochner BS, MacGlashan DW Jr, and Dispenza MC
- Abstract
IgE-mediated anaphylaxis is a potentially fatal systemic allergic reaction for which there are no known preventative therapies. Bruton's tyrosine kinase (BTK) is an essential enzyme for IgE-mediated signaling pathways, and is an ideal pharmacologic target to prevent allergic reactions. In this open-label trial (NCT05038904), we evaluated the safety and efficacy of acalabrutinib, a BTK inhibitor that is FDA-approved to treat some B cell malignancies, in preventing clinical reactivity to peanut in adults with IgE-mediated peanut allergy. After undergoing a graded oral peanut challenge to establish their baseline level of clinical reactivity, all patients then received four standard doses of 100 mg acalabrutinib twice daily and underwent repeat food challenge. The primary endpoint was the change in patients' threshold dose of peanut protein to elicit an objective clinical reaction. At baseline, patients tolerated a median of 29 mg of peanut protein before objective clinical reaction. During subsequent food challenge on acalabrutinib, patients' median tolerated dose significantly increased to 4,044 mg (range, 444 - 4,044 mg). 7 of 10 patients tolerated the maximum protocol amount (4,044 mg) of peanut protein with no objective clinical reaction, and the other 3 patients' peanut tolerance increased between 32- and 217-fold. Three patients experienced a total of 4 adverse events that were considered by the investigators to be possibly related to acalabrutinib; all events were transient and nonserious. These results demonstrate that acalabrutinib pretreatment can achieve clinically-relevant increases in patients' tolerance to their food allergen, thereby supporting the need for larger, placebo-controlled trials.
- Published
- 2023
- Full Text
- View/download PDF
19. Siglecs in allergy and asthma.
- Author
-
Bochner BS, O'Sullivan JA, Chang AT, and Youngblood BA
- Subjects
- Humans, Sialic Acid Binding Immunoglobulin-like Lectins metabolism, Antigens, CD, Signal Transduction, Hypersensitivity, Asthma therapy
- Abstract
The term "allergic diseases" encompasses several common, IgE-mediated conditions that range from being annoying to those that are life-threatening. Available treatments include active avoidance of the instigating allergen and the use of a variety of oral, inhaled, intranasal, intraocular and injected agents. While most individuals with allergies do well with existing therapies, there are still unmet therapeutic needs. Siglecs (sialic acid-binding, immunoglobulin-like lectins) are a family of single-pass transmembrane I-type lectins found on various subsets of cells, especially those of the immune system. All Siglecs have extracellular domains recognizing sialoside ligands, and most contain cytoplasmic domains with inhibitory signaling activity. This review focuses on Siglecs that likely play a role in regulating allergic and asthmatic responses, and how specific Siglecs, expressed on cells such as eosinophils and mast cells, are being targeted for therapeutic benefit., Competing Interests: Declaration of competing interest B.S.B. receives remuneration for serving on the scientific advisory board of Allakos, Inc. and owns stock in Allakos. He receives publication-related royalty payments from Elsevier and UpToDate. He is a co-inventor on existing Siglec-8–related patents and thus may be entitled to a share of royalties received by Johns Hopkins University during development and potential sales of such products. B.S.B. is also a co-founder of Allakos, Inc. which makes him subject to certain restrictions under University policy. The terms of this arrangement are being managed by Johns Hopkins University and Northwestern University in accordance with their conflict of interest policies. J.A.O. has nothing to disclose. A.T.C and B.A.Y. are current employees of and/or own stock and/or stock options from Allakos, Inc., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
20. Drug delivery targets and strategies to address mast cell diseases.
- Author
-
Rische CH, Thames AN, Krier-Burris RA, O'Sullivan JA, Bochner BS, and Scott EA
- Subjects
- Humans, Drug Delivery Systems, Mast Cells metabolism, Mast Cells pathology, Biological Products, Neoplasms drug therapy, Mast Cell Activation Disorders, Hypersensitivity drug therapy, Hypersensitivity metabolism, Hypersensitivity pathology
- Abstract
Introduction: Current and developing mast cell therapeutics are reliant on small molecule drugs and biologics, but few are truly selective for mast cells. Most have cellular and disease-specific limitations that require innovation to overcome longstanding challenges to selectively targeting and modulating mast cell behavior. This review is designed to serve as a frame of reference for new approaches that utilize nanotechnology or combine different drugs to increase mast cell selectivity and therapeutic efficacy., Areas Covered: Mast cell diseases include allergy and related conditions as well as malignancies. Here, we discuss the targets of existing and developing therapies used to treat these disease pathologies, classifying them into cell surface, intracellular, and extracellular categories. For each target discussed, we discuss drugs that are either the current standard of care, under development, or have indications for potential use. Finally, we discuss how novel technologies and tools can be used to take existing therapeutics to a new level of selectivity and potency against mast cells., Expert Opinion: There are many broadly and very few selectively targeted therapeutics for mast cells in allergy and malignant disease. Combining existing targeting strategies with technology like nanoparticles will provide novel platforms to treat mast cell disease more selectively.
- Published
- 2023
- Full Text
- View/download PDF
21. Bioactive multi-protein adsorption enables targeted mast cell nanotherapy.
- Author
-
Du F, Rische CH, Li Y, Vincent MP, Krier-Burris RA, Qian Y, Yuk SA, Almunif S, Bochner BS, Qiao B, and Scott EA
- Abstract
Competing Interests: Competing interests The authors declare no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
22. Urine eosinophil-derived neurotoxin: A potential marker of activity in select eosinophilic disorders.
- Author
-
Makiya MA, Khoury P, Kuang FL, Mata AD, Mahmood S, Bowman A, Espinoza D, Kovacs N, Brown T, Holland N, Wetzler L, Ware JM, Dyer AM, Akuthota P, Bochner BS, Chinchilli VM, Gleich GJ, Langford C, Merkel PA, Specks U, Weller PF, Wechsler ME, Prussin C, Fay MP, and Klion AD
- Subjects
- Humans, Eosinophil-Derived Neurotoxin, Prednisone, Reproducibility of Results, Eosinophils, Biomarkers, Churg-Strauss Syndrome, Granulomatosis with Polyangiitis
- Abstract
Background: Biomarkers of eosinophilic disease activity, especially in the context of novel therapies that reduce blood eosinophil counts, are an unmet need. Absolute eosinophil count (AEC) does not accurately reflect tissue eosinophilia or eosinophil activation. Therefore, the aims of this study were to compare the reliability of plasma and urine eosinophil major basic protein 1, eosinophil cationic protein, eosinophil-derived neurotoxin (EDN), and eosinophil peroxidase measurement and to evaluate the usefulness of eosinophil granule protein (EGP) measurement for the assessment of disease activity in patients with eosinophil-associated diseases treated with mepolizumab, benralizumab, or dexpramipexole., Methods: Eosinophil granule protein concentrations were measured in serum, plasma, and urine from healthy volunteers and patients with hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA), and eosinophilic asthma using a multiplex assay., Results: Urine EGP concentrations remained stable, whereas serum and plasma EGP concentrations increased significantly with delayed processing. Plasma (p) EDN, but not urine (u) EDN, concentration correlated with AEC and negatively correlated with prednisone dose. Both pEDN and uEDN decreased significantly following treatment of HES patients with benralizumab and EGPA patients with mepolizumab. uEDN appeared to increase with clinical relapse in both patient groups., Conclusions: Measurement of EGP in urine is noninvasive and unaffected by cellular lysis. Although plasma and urine EDN concentrations showed a similar pattern following benralizumab and mepolizumab treatment, the lack of correlation between AEC or prednisone dose and uEDN concentrations suggests that measurement of uEDN may provide a potential biomarker of disease activity in patients with HES and EGPA., (© 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.)
- Published
- 2023
- Full Text
- View/download PDF
23. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.
- Author
-
Valent P, Klion AD, Roufosse F, Simon D, Metzgeroth G, Leiferman KM, Schwaab J, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Hoermann G, Haferlach T, Moriggl R, George TI, Akin C, Bochner BS, Gotlib J, Reiter A, Horny HP, Arock M, Simon HU, and Gleich GJ
- Subjects
- Humans, Eosinophils pathology, Syndrome, Eosinophilia diagnosis, Eosinophilia etiology, Eosinophilia drug therapy, Hypersensitivity complications, Hypereosinophilic Syndrome etiology, Hypereosinophilic Syndrome complications
- Abstract
Eosinophilia and eosinophil activation are recurrent features in various reactive states and certain hematologic malignancies. In patients with hypereosinophilia (HE), HE-induced organ damage is often encountered and may lead to the diagnosis of a hypereosinophilic syndrome (HES). A number of known mechanisms and etiologies contribute to the development of HE and HES. Based on these etiologies and the origin of eosinophils, HE and HES are divided into primary forms where eosinophils are clonal cells, reactive forms where an underlying reactive or neoplastic condition is detected and eosinophils are considered to be "non-clonal" cells, and idiopathic HE and HES in which neither a clonal nor a reactive underlying pathology is detected. Since 2012, this classification and the related criteria have been widely accepted and regarded as standard. However, during the past few years, new developments in the field and an increasing number of markers and targets have created a need to update these criteria and the classification of HE and HES. To address this challenge, a Working Conference on eosinophil disorders was organized in 2021. In this conference, a panel of experts representing the relevant fields, including allergy, dermatology, hematology, immunology, laboratory medicine, and pathology, met and discussed new markers and concepts as well as refinements in definitions, criteria and classifications of HE and HES. The outcomes of this conference are presented in this article and should assist in the diagnosis and management of patients with HE and HES in daily practice and in the preparation and conduct of clinical trials., (© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
24. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
- Author
-
Chen MM, Roufosse F, Wang SA, Verstovsek S, Durrani SR, Rothenberg ME, Pongdee T, Butterfield J, Lax T, Wechsler ME, Stein ML, Ogbogu PU, Kahwash BM, Mathur SK, Simon D, Akuthota P, Holland N, Wetzler L, Ware JM, Guo C, Fay MP, Khoury P, Klion AD, and Bochner BS
- Subjects
- Alemtuzumab therapeutic use, Glucocorticoids therapeutic use, Humans, Interleukin-5, Off-Label Use, Retrospective Studies, Biological Products therapeutic use, Hypereosinophilic Syndrome drug therapy
- Abstract
Background: Treatment of hypereosinophilic syndrome (HES) often requires the use of immunomodulators with substantial side effect profiles. The emergence of biologics offers an alternative treatment modality., Objective: To examine real-world practice data to describe the safety and consequences of various biologics suspected to directly or indirectly affect eosinophilic inflammation for the treatment of HES., Methods: Retrospective data from 13 centers were collected via an online Research Electronic Data Capture repository. Inclusion criteria included (1) peripheral eosinophil count of 1,500/mm
3 or greater without a secondary cause; (2) clinical manifestations attributable to the eosinophilia; and (3) having received mepolizumab (anti-IL-5), benralizumab (afucosylated anti-IL-5 receptor α), omalizumab (anti-IgE), alemtuzumab (anti-CD52), dupilumab (anti-IL-4 receptor α), or reslizumab (anti-IL-5) outside a placebo-controlled clinical trial., Results: Of the 151 courses of biologics prescribed for 121 patients with HES, 59% resulted in improved HES symptoms and 77% enabled tapering of other HES medications. Overall, 105 patients were receiving daily systemic glucocorticoids at the time of a biologic initiation and were able to reduce the glucocorticoid dose by a median reduction of 10 mg of daily prednisone equivalents. Biologics were generally safe and well-tolerated other than infusion reactions with alemtuzumab. Thirteen of 24 patients had clinical improvement after switching biologics and nine patients responded to increasing the dose of mepolizumab after a lack of response to a lower dose., Conclusions: Biologics may offer a safer treatment alternative to existing therapies for HES, although the optimal dosing and choice for each subtype of HES remain to be determined. Limitations of this study include its retrospective nature and intersite differences in data collection and availability of each biologic., (Copyright © 2022 American Academy of Allergy, Asthma & Immunology. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
25. Functional and Phenotypic Characterization of Siglec-6 on Human Mast Cells.
- Author
-
Robida PA, Rische CH, Morgenstern NB, Janarthanam R, Cao Y, Krier-Burris RA, Korver W, Xu A, Luu T, Schanin J, Leung J, Rothenberg ME, Wechsler JB, Youngblood BA, Bochner BS, and O'Sullivan JA
- Subjects
- Cell Line, Humans, Antigens, CD genetics, Antigens, CD metabolism, Antigens, Differentiation, Myelomonocytic genetics, Lectins genetics, Mast Cells metabolism, Sialic Acid Binding Immunoglobulin-like Lectins genetics
- Abstract
Mast cells are tissue-resident cells that contribute to allergic diseases, among others, due to excessive or inappropriate cellular activation and degranulation. Therapeutic approaches to modulate mast cell activation are urgently needed. Siglec-6 is an immunoreceptor tyrosine-based inhibitory motif (ITIM)-bearing receptor selectively expressed by mast cells, making it a promising target for therapeutic intervention. However, the effects of its engagement on mast cells are poorly defined. Siglec-6 expression and endocytosis on primary human mast cells and mast cell lines were assessed by flow cytometry. SIGLEC6 mRNA expression was examined by single-cell RNAseq in esophageal tissue biopsy samples. The ability of Siglec-6 engagement or co-engagement to prevent primary mast cell activation was determined based on assessments of mediator and cytokine secretion and degranulation markers. Siglec-6 was highly expressed by all mast cells examined, and the SIGLEC6 transcript was restricted to mast cells in esophageal biopsy samples. Siglec-6 endocytosis occurred with delayed kinetics relative to the related receptor Siglec-8. Co-crosslinking of Siglec-6 with FcεRIα enhanced the inhibition of mast cell activation and diminished downstream ERK1/2 and p38 phosphorylation. The selective, stable expression and potent inhibitory capacity of Siglec-6 on human mast cells are favorable for its use as a therapeutic target in mast cell-driven diseases.
- Published
- 2022
- Full Text
- View/download PDF
26. Siglec-F Promotes IL-33-Induced Cytokine Release from Bone Marrow-Derived Eosinophils Independently of the ITIM and ITIM-like Motif Phosphorylation.
- Author
-
Westermann S, Dietschmann A, Doehler D, Castiglione K, Bochner BS, Voehringer D, and Radtke D
- Subjects
- Animals, Apoptosis immunology, Aspergillosis pathology, Aspergillus fumigatus immunology, Bone Marrow Cells cytology, Bone Marrow Cells metabolism, Cells, Cultured, Chemokine CCL3 metabolism, Chemokine CCL4 metabolism, Humans, Interleukin-13 metabolism, Interleukin-33 immunology, Interleukin-4 metabolism, Mice, Mice, Inbred C57BL, Mice, Knockout, Phosphorylation, STAT6 Transcription Factor metabolism, Sialic Acid Binding Immunoglobulin-like Lectins genetics, Aspergillosis immunology, Eosinophilia immunology, Eosinophils immunology, Interleukin-33 metabolism, Sialic Acid Binding Immunoglobulin-like Lectins metabolism
- Abstract
Eosinophils are potent innate effector cells associated mainly with type 2 immune responses elicited by helminths and allergens. Their activity needs to be tightly controlled to prevent severe inflammation and tissue damage. Eosinophil degranulation and secretion of inflammatory effector molecules, including cytokines, chemokines, and lipid mediators, can be regulated by activating and inhibitory receptors on the cell surface. In this study, we investigated the modulation of proliferation, apoptosis, gene expression, and cytokine/chemokine secretion from IL-33-activated Mus musculus eosinophils on cross-linking of the transmembrane receptor Sialic acid-binding Ig-like lectin F (Siglec-F). Siglec-F contains an ITIM plus an ITIM-like motif in its intracellular tail and is mainly regarded as an inhibitory and apoptosis-inducing receptor. In vitro costimulation of bone marrow-derived eosinophils with anti-Siglec-F and IL-33 compared with treatment with either alone led to enhanced STAT6 phosphorylation, stronger induction of hypoxia/glycolysis-related proinflammatory genes, and elevated secretion of type 2 cytokines (IL-4, IL-13) and chemokines (CCL3, CCL4) with only minor effects on proliferation and apoptosis. Using a competitive mixed bone marrow chimera approach with wild-type and Siglec-F-deficient eosinophils, we observed no evidence for Siglec-F-regulated inhibition of Aspergillus fumigatus -elicited lung eosinophilia. Truncation of the Siglec-F cytoplasmic tail, but not mutation of the ITIM and ITIM-like motifs, ablated the effect of enhanced cytokine/chemokine secretion. This provides evidence for an ITIM phosphorylation-independent signaling pathway from the cytoplasmic tail of the Siglec-F receptor that enhances effector molecule release from activated eosinophils., (Copyright © 2022 by The American Association of Immunologists, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
27. COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol.
- Author
-
Patel GB, Chhiba KD, Chen MM, Guo A, Watts MM, Cullen J, Bochner BS, Grammer LC, Greenberger PA, Saltoun CA, Stevens WW, Kuang FL, and Peters AT
- Subjects
- Adult, Aged, COVID-19 epidemiology, COVID-19 Vaccines administration & dosage, Female, Humans, Male, Middle Aged, Retrospective Studies, SARS-CoV-2, Vaccines, Synthetic administration & dosage, mRNA Vaccines, Anaphylaxis chemically induced, COVID-19 prevention & control, COVID-19 Vaccines adverse effects, Hypersensitivity, Vaccines, Synthetic adverse effects
- Abstract
Background: Acute allergic reactions to messenger RNA (mRNA) vaccines are rare but may limit public health immunization efforts. Objectives: To characterize suspected allergic reactions to the first dose of coronavirus disease 2019 (COVID-19) mRNA vaccine and to assess the safety and utility of a two-step graded-dose protocol for the second dose of the Pfizer-BioNTech vaccine in patients with a history of low suspicion of anaphylaxis to their first dose. Methods: This was a retrospective evaluation of referrals to the allergy and immunology clinic for a presumed allergic reaction to the first dose of the COVID-19 mRNA vaccine (Pfizer-BioNTech or Moderna) between December 17, 2020, and February 28, 2021. Recommendations for the second dose and outcomes were evaluated by trained board-certified allergists. Results: Seventy-seven patients presented with a Pfizer-BioNTech reaction (56 [72.7%]) or with a Moderna reaction (21 [27.3%]). Most patients (69.7%) had symptom onset within 4 hours. Most commonly reported symptoms were cutaneous (51.9%), cardiovascular (48.1%), and respiratory (33.8%) symptoms. Recommendations included to proceed with the single dose (70.1%), two-step graded dose (19.5%), or deferral (10.4%). Twelve of 15 patients completed the second dose with a graded-dose protocol. Of these patients, five reported at least one or more similar symptoms as experienced with their first dose. Conclusion: Of the patients with presumed allergic reactions to their first dose of COVID-19 mRNA vaccine, most were able to safely receive the second dose. For those with a low suspicion of anaphylaxis, the two-step graded protocol with the Pfizer-BioNTech vaccine was well tolerated. A graded-dose protocol could be an effective strategy for second-dose vaccination in those who may otherwise defer the second dose.
- Published
- 2021
- Full Text
- View/download PDF
28. Siglec-8 Signals Through a Non-Canonical Pathway to Cause Human Eosinophil Death In Vitro .
- Author
-
Carroll DJ, Cao Y, Bochner BS, and O'Sullivan JA
- Subjects
- Agammaglobulinaemia Tyrosine Kinase metabolism, CD11b Antigen metabolism, Cell Death, Cells, Cultured, Eosinophils drug effects, Eosinophils immunology, Eosinophils pathology, Humans, Interleukin-5 pharmacology, Mitogen-Activated Protein Kinase Kinases metabolism, Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases metabolism, Protein Kinase C metabolism, Reactive Oxygen Species metabolism, Signal Transduction, Syk Kinase metabolism, Type C Phospholipases metabolism, p21-Activated Kinases metabolism, src-Family Kinases metabolism, Antigens, CD metabolism, Antigens, Differentiation, B-Lymphocyte metabolism, Eosinophils metabolism, Lectins metabolism
- Abstract
Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is a glycan-binding receptor bearing immunoreceptor tyrosine-based inhibitory and switch motifs (ITIM and ITSM, respectively) that is selectively expressed on eosinophils, mast cells, and, to a lesser extent, basophils. Previous work has shown that engagement of Siglec-8 on IL-5-primed eosinophils causes cell death via CD11b/CD18 integrin-mediated adhesion and NADPH oxidase activity and identified signaling molecules linking adhesion, reactive oxygen species (ROS) production, and cell death. However, the proximal signaling cascade activated directly by Siglec-8 engagement has remained elusive. Most members of the Siglec family possess similar cytoplasmic signaling motifs and recruit the protein tyrosine phosphatases SHP-1/2, consistent with ITIM-mediated signaling, to dampen cellular activation. However, the dependence of Siglec-8 function in eosinophils on these phosphatases has not been studied. Using Siglec-8 antibody engagement and pharmacological inhibition in conjunction with assays to measure cell-surface upregulation and conformational activation of CD11b integrin, ROS production, and cell death, we sought to identify molecules involved in Siglec-8 signaling and determine the stage of the process in which each molecule plays a role. We demonstrate here that the enzymatic activities of Src family kinases (SFKs), Syk, SHIP1, PAK1, MEK1, ERK1/2, PLC, PKC, acid sphingomyelinase/ceramidase, and Btk are all necessary for Siglec-8-induced eosinophil cell death, with no apparent role for SHP-1/2, SHIP2, or c-Raf. While most of these signaling molecules are necessary for Siglec-8-induced upregulation of CD11b integrin at the eosinophil cell surface, Btk is phosphorylated and activated later in the signaling cascade and is instead necessary for CD11b activation. In contrast, SFKs and ERK1/2 are phosphorylated far earlier in the process, consistent with their role in augmenting cell-surface levels of CD11b. In addition, pretreatment of eosinophils with latrunculin B or jasplakinolide revealed that actin filament disassembly is necessary and sufficient for surface CD11b integrin upregulation and that actin polymerization is necessary for downstream ROS production. These results show that Siglec-8 signals through an unanticipated set of signaling molecules in IL-5-primed eosinophils to induce cell death and challenges the expectation that ITIM-bearing Siglecs signal through inhibitory pathways involving protein tyrosine phosphatases to achieve their downstream functions., Competing Interests: BB received remuneration for serving on the scientific advisory board of Allakos, Inc. and owns stock in Allakos. He receives publication-related royalty payments from Elsevier and UpToDate®. He is a co-inventor on existing Siglec-8–related patents and thus may be entitled to a share of royalties received by Johns Hopkins University during development and potential sales of such products. BB is also a co-founder of Allakos, which makes him subject to certain restrictions under University policy. The terms of this arrangement are being managed by Johns Hopkins University and Northwestern University in accordance with their conflict of interest policies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Carroll, Cao, Bochner and O’Sullivan.)
- Published
- 2021
- Full Text
- View/download PDF
29. Legends of allergy and immunology: Robert P. Schleimer.
- Author
-
Kato A, Stevens WW, and Bochner BS
- Subjects
- Chronic Disease, Eosinophils, Humans, Hypersensitivity, Nasal Polyps, Rhinitis, Sinusitis
- Published
- 2021
- Full Text
- View/download PDF
30. Rethinking neutrophils and eosinophils in chronic rhinosinusitis.
- Author
-
Delemarre T, Bochner BS, Simon HU, and Bachert C
- Subjects
- Chronic Disease, Eosinophils pathology, Humans, Inflammation immunology, Inflammation pathology, Inflammation therapy, Nasal Polyps immunology, Nasal Polyps pathology, Nasal Polyps therapy, Neutrophils pathology, Rhinitis pathology, Rhinitis therapy, Severity of Illness Index, Sinusitis pathology, Sinusitis therapy, Eosinophils immunology, Neutrophils immunology, Rhinitis immunology, Sinusitis immunology
- Abstract
Chronic rhinosinusitis (CRS) often is characterized by an eosinophilic inflammatory pattern, nowadays referred to as type 2 inflammation, although the mucosal inflammation is dominated by neutrophils in about a third of the patients. Neutrophils are typically predominant in 50% of patients with CRS without nasal polyps, but also are found to play a role in patients with severe type 2 CRS with nasal polyp disease. This review aims at summarizing the current understanding of the eosinophilic and neutrophilic inflammation in CRS pathophysiology, and provides a discussion of their reciprocal interactions and the clinical impact of the mixed presentation in patients with severe type 2 CRS with nasal polyps. A solid understanding of these interactions is of utmost importance when treating uncontrolled severe CRS with nasal polyps with biologicals that are preferentially directed toward type 2 inflammation. We here focus on recent findings on both eosinophilic and neutrophilic granulocytes, their subgroups and the activation status, and their interactions in CRS., (Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
31. Lessons learned from targeting eosinophils in human disease.
- Author
-
Kuang FL and Bochner BS
- Subjects
- Animals, Humans, Mice, Phenotype, Eosinophils, Immunity, Innate
- Abstract
Eosinophils are a minor subset of the granulocyte lineage distinguished by their unique morphology, phenotype, cytoplasmic contents, and function. Evolutionarily, these are ancient cells whose existence has been conserved within vertebrates for millions of years, suggesting that their contribution to innate immunity and other pathologic and homeostatic responses are important to the host. Knowledge regarding the role of eosinophils in health and disease took a leap forward in 2004 with the creation of mouse strains deficient in eosinophils. This advance was paralleled in humans using pharmacology, namely, with the development of drugs capable of selectively reducing and sometimes even eliminating human eosinophils in those receiving these agents. As a result, a more definitive picture of what eosinophils do, and do not do, is emerging. This review will summarize recent advances in our understanding of the role of eosinophils in human disease by focusing mainly on data from clinical studies with anti-eosinophil therapies, even though the first of such agents, mepolizumab, was only approved in the USA in November 2015. Information regarding both efficacy and safety will be highlighted, and where relevant, intriguing data from animal models will also be mentioned, especially if there are conflicting effects seen in humans.
- Published
- 2021
- Full Text
- View/download PDF
32. Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.
- Author
-
Valent P, Degenfeld-Schonburg L, Sadovnik I, Horny HP, Arock M, Simon HU, Reiter A, and Bochner BS
- Subjects
- Cytokines, Eosinophils, Humans, Hematologic Neoplasms, Hypereosinophilic Syndrome diagnosis, Hypereosinophilic Syndrome etiology, Hypereosinophilic Syndrome therapy
- Abstract
Eosinophils and their mediators play a crucial role in various reactive states such as bacterial and viral infections, chronic inflammatory disorders, and certain hematologic malignancies. Depending on the underlying pathology, molecular defect(s), and the cytokine- and mediator-cascades involved, peripheral blood and tissue hypereosinophilia (HE) may develop and may lead to organ dysfunction or even organ damage which usually leads to the diagnosis of a HE syndrome (HES). In some of these patients, the etiology and impact of HE remain unclear. These patients are diagnosed with idiopathic HE. In other patients, HES is diagnosed but the etiology remains unknown - these patients are classified as idiopathic HES. For patients with HES, early therapeutic application of agents reducing eosinophil counts is usually effective in avoiding irreversible organ damage. Therefore, it is important to systematically explore various diagnostic markers and to correctly identify the disease elicitors and etiology. Depending on the presence and type of underlying disease, HES are classified into primary (clonal) HES, reactive HES, and idiopathic HES. In most of these patients, effective therapies can be administered. The current article provides an overview of the pathogenesis of eosinophil-associated disorders, with special emphasis on the molecular, immunological, and clinical complexity of HE and HES. In addition, diagnostic criteria and the classification of eosinophil disorders are reviewed in light of new developments in the field.
- Published
- 2021
- Full Text
- View/download PDF
33. Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: Prompt resolution of anaphylaxis with the addition of avapritinib.
- Author
-
Kudlaty E, Perez M, Stein BL, Bochner BS, and Kuang FL
- Subjects
- Humans, Mast Cells, Pyrazoles, Pyrroles, Triazines, Tryptases, Anaphylaxis diagnosis, Anaphylaxis drug therapy, Hematologic Neoplasms, Mastocytosis, Mastocytosis, Systemic diagnosis, Mastocytosis, Systemic drug therapy
- Published
- 2021
- Full Text
- View/download PDF
34. Nanoparticles Displaying Allergen and Siglec-8 Ligands Suppress IgE-FcεRI-Mediated Anaphylaxis and Desensitize Mast Cells to Subsequent Antigen Challenge.
- Author
-
Duan S, Arlian BM, Nycholat CM, Wei Y, Tateno H, Smith SA, Macauley MS, Zhu Z, Bochner BS, and Paulson JC
- Subjects
- Anaphylaxis immunology, Animals, Antigens, CD genetics, Antigens, Differentiation, B-Lymphocyte genetics, Cell Degranulation drug effects, Cell Degranulation genetics, Cell Degranulation immunology, Cell Line, Tumor, Disease Models, Animal, Humans, Lectins genetics, Ligands, Liposomes, Mice, Mice, Inbred C57BL, Mice, Transgenic, Polysaccharides metabolism, Rats, Receptors, IgE genetics, Treatment Outcome, Allergens administration & dosage, Anaphylaxis drug therapy, Anaphylaxis genetics, Antigens, CD metabolism, Antigens, Differentiation, B-Lymphocyte metabolism, Desensitization, Immunologic methods, Drug Delivery Systems methods, Immunoglobulin E metabolism, Lectins metabolism, Mast Cells immunology, Nanoparticles chemistry, Polysaccharides administration & dosage, Receptors, IgE metabolism
- Abstract
Siglec-8 is an inhibitory receptor expressed on eosinophils and mast cells. In this study, we took advantage of a novel Siglec-8 transgenic mouse model to assess the impact of modulating IgE-dependent mast cell degranulation and anaphylaxis using a liposomal platform to display an allergen with or without a synthetic glycan ligand for Siglec-8 (Sig8L). The hypothesis is that recruitment of Siglec-8 to the IgE-FcεRI receptor complex will inhibit allergen-induced mast cell degranulation. Codisplay of both allergen and Sig8L on liposomes profoundly suppresses IgE-mediated degranulation of mouse bone marrow-derived mast cells or rat basophilic leukemia cells expressing Siglec-8. In contrast, liposomes displaying only Sig8L have no significant suppression of antigenic liposome-induced degranulation, demonstrating that the inhibitory activity by Siglec-8 occurs only when Ag and Sig8L are on the same particle. In mouse models of anaphylaxis, display of Sig8L on antigenic liposomes completely suppresses IgE-mediated anaphylaxis in transgenic mice with mast cells expressing Siglec-8 but has no protection in mice that do not express Siglec-8. Furthermore, mice protected from anaphylaxis remain desensitized to subsequent allergen challenge because of loss of Ag-specific IgE from the cell surface and accelerated clearance of IgE from the blood. Thus, although expression of human Siglec-8 on murine mast cells does not by itself modulate IgE-FcεRI-mediated cell activation, the enforced recruitment of Siglec-8 to the FcεRI receptor by Sig8L-decorated antigenic liposomes results in inhibition of degranulation and desensitization to subsequent Ag exposure., (Copyright © 2021 by The American Association of Immunologists, Inc.)
- Published
- 2021
- Full Text
- View/download PDF
35. Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody.
- Author
-
Gebremeskel S, Schanin J, Coyle KM, Butuci M, Luu T, Brock EC, Xu A, Wong A, Leung J, Korver W, Morin RD, Schleimer RP, Bochner BS, and Youngblood BA
- Subjects
- Animals, Antibodies, Monoclonal pharmacology, Antigens, CD genetics, Antigens, CD metabolism, Antigens, Differentiation, B-Lymphocyte genetics, Antigens, Differentiation, B-Lymphocyte metabolism, COVID-19 metabolism, COVID-19 prevention & control, COVID-19 virology, Case-Control Studies, Cytokines metabolism, Disease Models, Animal, Eosinophils drug effects, Eosinophils metabolism, Eosinophils virology, Host-Pathogen Interactions, Humans, Lectins antagonists & inhibitors, Lectins genetics, Lectins metabolism, Mast Cells drug effects, Mast Cells metabolism, Mast Cells virology, Mice, Transgenic, Peptide Hydrolases metabolism, Respiratory Syncytial Virus Infections metabolism, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Infections virology, Toll-Like Receptors metabolism, Antigens, CD immunology, Antigens, Differentiation, B-Lymphocyte immunology, COVID-19 immunology, Eosinophils immunology, Lectins immunology, Mast Cells immunology, Respiratory Syncytial Virus Infections immunology, Respiratory Syncytial Viruses immunology, SARS-CoV-2 immunology, Toll-Like Receptors immunology
- Abstract
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection represents a global health crisis. Immune cell activation via pattern recognition receptors has been implicated as a driver of the hyperinflammatory response seen in COVID-19. However, our understanding of the specific immune responses to SARS-CoV-2 remains limited. Mast cells (MCs) and eosinophils are innate immune cells that play pathogenic roles in many inflammatory responses. Here we report MC-derived proteases and eosinophil-associated mediators are elevated in COVID-19 patient sera and lung tissues. Stimulation of viral-sensing toll-like receptors in vitro and administration of synthetic viral RNA in vivo induced features of hyperinflammation, including cytokine elevation, immune cell airway infiltration, and MC-protease production-effects suppressed by an anti-Siglec-8 monoclonal antibody which selectively inhibits MCs and depletes eosinophils. Similarly, anti-Siglec-8 treatment reduced disease severity and airway inflammation in a respiratory viral infection model. These results suggest that MC and eosinophil activation are associated with COVID-19 inflammation and anti-Siglec-8 antibodies are a potential therapeutic approach for attenuating excessive inflammation during viral infections., Competing Interests: JS, SG, MB, TL, EB, AX, AW, JL,WK, and BY are employees of Allakos and/or own stock options in Allakos. BB and RS did not perform any of the experiments but are paid consultants on the scientific advisory board of Allakos, Inc., and own stock in Allakos. BB and RS are coinventors on existing Siglec-8–related patents and thus may be entitled to a share of royalties received by Johns Hopkins University from Allakos, Inc. on the potential sales of such products. BB and RS are also cofounders of Allakos, which makes him subject to certain restrictions under university policy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Gebremeskel, Schanin, Coyle, Butuci, Luu, Brock, Xu, Wong, Leung, Korver, Morin, Schleimer, Bochner and Youngblood.)
- Published
- 2021
- Full Text
- View/download PDF
36. Biology and Function of Eosinophils in Chronic Rhinosinusitis With or Without Nasal Polyps.
- Author
-
Bochner BS and Stevens WW
- Abstract
Chronic rhinosinusitis (CRS) with or without nasal polyposis is a complex medical condition characterized by varying patterns of chronic innate and adaptive mucosal inflammation. Treatment of CRS has been traditionally limited to corticosteroids and sinus surgery; however, novel biologics have more recently been evaluated as steroid- and surgery-sparing options. While it is clear that there are different subtypes or endotypes of CRS, perhaps the most frequent presentation involves the features of type 2 inflammation, including a prominent tissue eosinophilia component. The purpose of this review is to provide an update on eosinophil biology as well as on the potential contribution of eosinophils and their mediators to the pathophysiology of CRS, drawing mechanistic conclusions mainly from studies of human sinus mucosal tissues, nasal secretions, and benefits (or lack thereof) from the use of various pharmacotherapies. The unavoidable conclusion derived from this approach is that eosinophils themselves cannot fully explain the underlying pathophysiology of this complex disorder., Competing Interests: B.S.B. receives remuneration for serving on the scientific advisory board of Allakos, Inc. and owns stock in Allakos. He has serves as a consultant to Sanofi-Regeneron and GlaxoSmithKline and receives publication-related royalty payments from Elsevier and UpToDate®. He is a co-inventor on existing Siglec-8-related patents and thus may be entitled to a share of royalties received by Johns Hopkins University during development and potential sales of such products. Dr. Bochner is also a co-founder of Allakos, which makes him subject to certain restrictions under University policy. The terms of this arrangement are being managed by Johns Hopkins University and Northwestern University in accordance with their conflict of interest policies. W.W.S. served on a scientific advisory board for GlaxoSmithKline., (Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology · The Korean Academy of Pediatric Allergy and Respiratory Disease.)
- Published
- 2021
- Full Text
- View/download PDF
37. Discovery, Function, and Therapeutic Targeting of Siglec-8.
- Author
-
Youngblood BA, Leung J, Falahati R, Williams J, Schanin J, Brock EC, Singh B, Chang AT, O'Sullivan JA, Schleimer RP, Tomasevic N, Bebbington CR, and Bochner BS
- Subjects
- Animals, Clinical Trials as Topic, Eosinophils pathology, Humans, Mast Cells pathology, Mice, Mice, Transgenic, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized pharmacology, Antigens, CD immunology, Antigens, CD physiology, Antigens, Differentiation, B-Lymphocyte immunology, Antigens, Differentiation, B-Lymphocyte physiology, Eosinophils immunology, Hypersensitivity drug therapy, Hypersensitivity immunology, Inflammation drug therapy, Inflammation immunology, Lectins immunology, Lectins physiology, Mast Cells immunology
- Abstract
Siglecs (sialic acid-binding immunoglobulin-like lectins) are single-pass cell surface receptors that have inhibitory activities on immune cells. Among these, Siglec-8 is a CD33-related family member selectively expressed on human mast cells and eosinophils, and at low levels on basophils. These cells can participate in inflammatory responses by releasing mediators that attract or activate other cells, contributing to the pathogenesis of allergic and non-allergic diseases. Since its discovery in 2000, initial in vitro studies have found that the engagement of Siglec-8 with a monoclonal antibody or with selective polyvalent sialoglycan ligands induced the cell death of eosinophils and inhibited mast cell degranulation. Anti-Siglec-8 antibody administration in vivo to humanized and transgenic mice selectively expressing Siglec-8 on mouse eosinophils and mast cells confirmed the in vitro findings, and identified additional anti-inflammatory effects. AK002 (lirentelimab) is a humanized non-fucosylated IgG1 antibody against Siglec-8 in clinical development for mast cell- and eosinophil-mediated diseases. AK002 administration has safely demonstrated the inhibition of mast cell activity and the depletion of eosinophils in several phase 1 and phase 2 trials. This article reviews the discovery and functions of Siglec-8, and strategies for its therapeutic targeting for the treatment of eosinophil- and mast cell-associated diseases.
- Published
- 2020
- Full Text
- View/download PDF
38. Targeting the FcεRI Pathway as a Potential Strategy to Prevent Food-Induced Anaphylaxis.
- Author
-
Dispenza MC, Bochner BS, and MacGlashan DW Jr
- Subjects
- Agammaglobulinaemia Tyrosine Kinase antagonists & inhibitors, Anaphylaxis immunology, Animals, Anti-Allergic Agents therapeutic use, Basophils immunology, Basophils metabolism, Humans, Mast Cells immunology, Mast Cells metabolism, Mice, Omalizumab therapeutic use, Signal Transduction genetics, Signal Transduction immunology, Agammaglobulinaemia Tyrosine Kinase metabolism, Anaphylaxis prevention & control, Food Hypersensitivity immunology, Immunoglobulin E immunology, Protein Tyrosine Phosphatases metabolism, Receptors, IgE metabolism, Sialic Acid Binding Immunoglobulin-like Lectins metabolism
- Abstract
Despite attempts to halt it, the prevalence of food allergy is increasing, and there is an unmet need for strategies to prevent morbidity and mortality from food-induced allergic reactions. There are no known medications that can prevent anaphylaxis, but several novel therapies show promise for the prevention of food-induced anaphylaxis through targeting of the high-affinity IgE receptor (FcϵRI) pathway. This pathway includes multiple candidate targets, including tyrosine kinases and the receptor itself. Small molecule inhibitors of essential kinases have rapid onset of action and transient efficacy, which may be beneficial for short-term use for immunotherapy buildup or desensitizations. Short courses of FDA-approved inhibitors of Bruton's tyrosine kinase can eliminate IgE-mediated basophil activation and reduce food skin test size in allergic adults, and prevent IgE-mediated anaphylaxis in humanized mice. In contrast, biologics may provide longer-lasting protection, albeit with slower onset. Omalizumab is an anti-IgE antibody that sequesters IgE, thereby reducing FcϵRI expression on mast cells and basophils. As a monotherapy, it can increase the clinical threshold dose of food allergen, and when used as an adjunct for food immunotherapy, it decreases severe reactions during buildup phase. Finally, lirentelimab, an anti-Siglec-8 antibody currently in clinical trials, can prevent IgE-mediated anaphylaxis in mice through mast cell inhibition. This review discusses these and other emerging therapies as potential strategies for preventing food-induced anaphylaxis. In contrast to other food allergy treatments which largely focus on individual allergens, blockade of the FcϵRI pathway has the advantage of preventing clinical reactivity from any food., Competing Interests: MD has received research funding from Acerta Pharma/AstraZeneca in addition to consultant fees from AlphaSights, BVF Partners, and DAVA Oncology. BB has also received research funding from Acerta Pharma/AstraZeneca, as well as consultant fees from Regeneron, Sanofi, and GlaxoSmithkline. Finally, BB receives remuneration for serving on the scientific advisory board of Allakos, Inc. and owns stock in Allakos. He is a co-inventor on existing Siglec-8–related patents and thus may be entitled to a share of royalties received by Johns Hopkins University during development and potential sales of such products. BB is also a co-founder of Allakos; the terms of this arrangement are being managed by Johns Hopkins University and Northwestern University in accordance with their conflict of interest policies. DM consults for Boehringer-Ingelheim., (Copyright © 2020 Dispenza, Bochner and MacGlashan.)
- Published
- 2020
- Full Text
- View/download PDF
39. Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis.
- Author
-
Dispenza MC, Krier-Burris RA, Chhiba KD, Undem BJ, Robida PA, and Bochner BS
- Subjects
- Agammaglobulinaemia Tyrosine Kinase immunology, Anaphylaxis immunology, Anaphylaxis pathology, Animals, Humans, Mice, Mice, Inbred NOD, Mice, SCID, Receptors, IgE immunology, Agammaglobulinaemia Tyrosine Kinase antagonists & inhibitors, Anaphylaxis prevention & control, Benzamides pharmacology, Immunoglobulin E immunology, Protein Kinase Inhibitors pharmacology, Pyrazines pharmacology
- Abstract
No known therapies can prevent anaphylaxis. Bruton's tyrosine kinase (BTK) is an enzyme thought to be essential for high-affinity IgE receptor (FcεRI) signaling in human cells. We tested the hypothesis that FDA-approved BTK inhibitors (BTKis) would prevent IgE-mediated responses including anaphylaxis. We showed that irreversible BTKis broadly prevented IgE-mediated degranulation and cytokine production in primary human mast cells and blocked allergen-induced contraction of isolated human bronchi. To address their efficacy in vivo, we created and used what we believe to be a novel humanized mouse model of anaphylaxis that does not require marrow ablation or human tissue implantation. After a single intravenous injection of human CD34+ cells, NSG-SGM3 mice supported the population of mature human tissue-resident mast cells and basophils. These mice showed excellent responses during passive systemic anaphylaxis using human IgE to selectively evoke human mast cell and basophil activation, and response severity was controllable by alteration of the amount of allergen used for challenge. Remarkably, pretreatment with just 2 oral doses of the BTKi acalabrutinib completely prevented moderate IgE-mediated anaphylaxis in these mice and also significantly protected against death during severe anaphylaxis. Our data suggest that BTKis may be able to prevent anaphylaxis in humans by inhibiting FcεRI-mediated signaling.
- Published
- 2020
- Full Text
- View/download PDF
40. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19.
- Author
-
Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, Mai Q, Yeh C, Muhammad LN, Harris KE, Bochner BS, Grammer LC, Greenberger PA, Kalhan R, Kuang FL, Saltoun CA, Schleimer RP, Stevens WW, and Peters AT
- Subjects
- Administration, Inhalation, Adrenal Cortex Hormones therapeutic use, Adult, Age Factors, Aged, Anti-Asthmatic Agents therapeutic use, Asthma diagnosis, Asthma drug therapy, Asthma physiopathology, COVID-19, COVID-19 Testing, Clinical Laboratory Techniques methods, Comorbidity, Coronary Artery Disease diagnosis, Coronary Artery Disease physiopathology, Coronavirus Infections diagnosis, Coronavirus Infections physiopathology, Diabetes Mellitus diagnosis, Diabetes Mellitus physiopathology, Female, Hospitalization statistics & numerical data, Humans, Hypertension diagnosis, Hypertension physiopathology, Illinois epidemiology, Male, Middle Aged, Models, Statistical, Obesity diagnosis, Obesity physiopathology, Pandemics, Pneumonia, Viral diagnosis, Pneumonia, Viral physiopathology, Prevalence, Retrospective Studies, Risk Factors, SARS-CoV-2, Asthma epidemiology, Betacoronavirus pathogenicity, Coronary Artery Disease epidemiology, Coronavirus Infections epidemiology, Diabetes Mellitus epidemiology, Hypertension epidemiology, Obesity epidemiology, Pneumonia, Viral epidemiology
- Abstract
Background: The Centers for Disease Control and Prevention advises that patients with moderate to severe asthma belong to a high-risk group that is susceptible to severe coronavirus disease 2019 (COVID-19). However, the association between asthma and COVID-19 has not been well-established., Objective: The primary objective was to determine the prevalence of asthma among patients with COVID-19 in a major US health system. We assessed the clinical characteristics and comorbidities in asthmatic and nonasthmatic patients with COVID-19. We also determined the risk of hospitalization associated with asthma and/or inhaled corticosteroid use., Methods: Medical records of patients with COVID-19 were searched by a computer algorithm (March 1 to April 15, 2020), and chart review was used to validate the diagnosis of asthma and medications prescribed for asthma. All patients had PCR-confirmed COVID-19. Demographic and clinical features were characterized. Regression models were used to assess the associations between asthma and corticosteroid use and the risk of COVID-19-related hospitalization., Results: Of 1526 patients identified with COVID-19, 220 (14%) were classified as having asthma. Asthma was not associated with an increased risk of hospitalization (relative risk, 0.96; 95% CI, 0.77-1.19) after adjusting for age, sex, and comorbidities. The ongoing use of inhaled corticosteroids did not increase the risk of hospitalization in a similar adjusted model (relative risk, 1.39; 95% CI, 0.90-2.15)., Conclusions: Despite a substantial prevalence of asthma in our COVID-19 cohort, asthma was not associated with an increased risk of hospitalization. Similarly, the use of inhaled corticosteroids with or without systemic corticosteroids was not associated with COVID-19-related hospitalization., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
41. Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features.
- Author
-
Dong ZM, Lin E, Wechsler ME, Weller PF, Klion AD, Bochner BS, Delker DA, Hazel MW, Fairfax K, Khoury P, Akuthota P, Merkel PA, Dyer AM, Langford C, Specks U, Gleich GJ, Chinchilli VM, Raby B, Yandell M, and Clayton F
- Subjects
- Adult, Churg-Strauss Syndrome pathology, Female, Granulomatosis with Polyangiitis pathology, Humans, Male, Churg-Strauss Syndrome immunology, Granulomatosis with Polyangiitis immunology, Immunoglobulin G immunology, Plasma Cells immunology
- Abstract
The immunologic mechanisms promoting eosinophilic granulomatosis with polyangiitis (EGPA) are unclear. To characterize the mechanisms underlying pulmonary EGPA, we examined and compared EGPA paraffin-embedded lung biopsies with normal lung biopsies, using immunostaining, RNA sequencing, and RT-PCR. The results revealed novel type 2 as well as immuneregulatory features. These features included basophils and increased mast cell contents; increased immunostaining for tumor necrosis factor ligand superfamily member 14; sparse mast cell degranulation; numerous forkhead box protein P3 (FoxP3)+ regulatory T cells and IgG4 plasma cells; and abundant arachidonate 15-lipoxygenase and 25-hydroxyvitamin D-1 α hydroxylase, mitochondrial. Significantly decreased 15-hydroxyprostaglandin dehydrogenase [NAD(
+ )], which degrades eicosanoids, was observed in EGPA samples. In addition, there was significantly increased mRNA for chemokine (C-C motif) ligands 18 and 13 and major collagen genes, IgG4-rich immune complexes coating alveolar macrophages, and increased immunostaining for phosphorylated mothers against decapentaplegic homolog 2/SMAD2, suggesting transforming growth factor-β activation. These findings suggest a novel self-promoting mechanism of activation of alveolar macrophages by arachidonate 15-lipoxygenase-derived eicosanoids to express chemokines that recruit a combined type 2/immunoregulatory immune response, which produces these eicosanoids. These results suggest that the pulmonary EGPA immune response resembles the immune response to a tissue-invasive parasite infection., (Copyright © 2020 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
42. Frontline Science: Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls.
- Author
-
Knuplez E, Krier-Burris R, Cao Y, Marsche G, O'Sullivan J, and Bochner BS
- Subjects
- Animals, Antibodies metabolism, Antibodies pharmacology, Biomarkers metabolism, Bone Marrow Cells cytology, CD11b Antigen metabolism, Cell Death drug effects, Cell Survival drug effects, Female, Injections, Male, Mice, Inbred C57BL, Mice, Transgenic, N-Acetylneuraminic Acid metabolism, Phenotype, Sialic Acid Binding Immunoglobulin-like Lectins, Spleen metabolism, Antigens, CD metabolism, Antigens, Differentiation, Myelomonocytic metabolism, Eosinophils metabolism
- Abstract
Eosinophils are important multifunctional granulocytes. When studying eosinophil function and its contribution to diseases, mouse models are often used. Mouse eosinophils selectively express sialic acid-binding immunoglobulin-like lectin (Siglec)-F. Its closest functional paralog on human eosinophils is Siglec-8. These Siglecs are being used to target eosinophils when exploring their mechanistic roles in disease and for potential therapeutic benefit. In order to facilitate preclinical studies of human Siglec-8, we developed transgenic mouse strains expressing human Siglec-8 only on the surface of eosinophils with or without endogenous Siglec-F and have begun characterizing various cellular functions in vitro and in vivo. Eosinophils from Siglec-8+ mice, with or without Siglec-F, responded to Siglec-8 antibody engagement in vitro by up-regulating surface CD11b, whereas Siglec-F antibody had no such effect. Engagement of Siglec-F or Siglec-8 with respective antibodies in vitro resulted in only modest increases in cell death. Administration of rat Siglec-F antibodies to mice led to a significant decrease in Siglec-F surface expression on eosinophils due to internalization, and thus appeared to decrease eosinophil numbers based on Siglec-F+ cells, but with proper gaiting strategies did not in fact result in significant eosinophil depletion. In marked contrast, administration of mouse Siglec-8 antibodies rapidly and effectively depleted eosinophils from blood and spleens of mice, but an F(ab')
2 version did not, indicating an Fc-mediated mechanism for eosinophil depletion in vivo. Siglec-8 expressing mice with or without endogenous Siglec-F will be useful to study Siglec-8-based therapeutics, and may be a preferred approach when acute or chronic eosinophil depletion is needed., (©2020 Society for Leukocyte Biology.)- Published
- 2020
- Full Text
- View/download PDF
43. Eosinophil and mast cell Siglecs: From biology to drug target.
- Author
-
O'Sullivan JA, Chang AT, Youngblood BA, and Bochner BS
- Subjects
- Animals, Clinical Trials as Topic, Disease Models, Animal, Humans, Drug Delivery Systems, Eosinophils metabolism, Mast Cells metabolism, Sialic Acid Binding Immunoglobulin-like Lectins metabolism
- Abstract
Mast cells and eosinophils are innate immune cells involved in both acute and chronic inflammatory responses. Siglecs are a family of cell surface receptors that share sialic acid binding activity. Over the past 20 years, our knowledge of the expression and function of Siglecs on cells of the immune system and others has greatly expanded, as has our understanding of their signaling, ligands, and possible roles in disease pathophysiology. Because of this, Siglecs have garnered interest as potential drug targets using strategies ranging from biologics to ligand-directed nanoparticles. This mini-review will highlight the state of our knowledge regarding human eosinophil and mast cell Siglecs, their biology, what they recognize, tools developed for in vitro and preclinical experimentation, and the status of ongoing efforts to develop drugs that engage eosinophil and mast cell Siglecs for potential therapeutic benefit., (©2020 Society for Leukocyte Biology.)
- Published
- 2020
- Full Text
- View/download PDF
44. Single-site, five-year experience with human eosinophil isolation by density gradient centrifugation and CD16 immunomagnetic negative separation.
- Author
-
Cao Y, Shin S, Carroll DJ, O'Sullivan JA, and Bochner BS
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Reproducibility of Results, Retrospective Studies, Young Adult, Centrifugation, Density Gradient standards, Eosinophils, Immunomagnetic Separation standards
- Abstract
Objective: Little has been reported regarding the reliability of methods for the purification of human blood eosinophils. We retrospectively reviewed our experience with 350 consecutive eosinophil isolations., Results: Between January 2014 and December 2018, we conducted 350 eosinophil purifications from 83 donors. Absolute eosinophil count (AEC), calculated from hospital complete blood counts when available (n = 289), ranged from 32 to 1352 eosinophils/µL ([Formula: see text]: 179 ± 136/µL). Eosinophil yields ranged from 0.4 to 24.4 million cells per 20 mL of blood drawn ([Formula: see text]: 3.1 ± 1.9 million eosinophils) with > 98% purity. Comparing AEC to actual yield, recovery was 87% ± 29% ([Formula: see text]) and AEC strongly correlated with yield. To explore the reproducibility of yield, a subsequent analysis was limited to those donors drawn ≥ 3 times (N = 35), and there was no difference in the average coefficient of variation for yield between allergic and non-allergic donors. Viability of isolated eosinophils was consistently > 95% and after 24 h of culture did not differ between allergic and non-allergic donors. We conclude that this immunomagnetic separation method for human eosinophil isolation from whole blood is a reliable, reproducible technique for obtaining an average of 87% yield with high purity and viability.
- Published
- 2020
- Full Text
- View/download PDF
45. Contributions of Eosinophils to Human Health and Disease.
- Author
-
Klion AD, Ackerman SJ, and Bochner BS
- Subjects
- Animals, Helminthiasis immunology, Humans, Leukocyte Count, Mice, Disease etiology, Eosinophils physiology, Immunity, Innate physiology
- Abstract
The human eosinophil has long been thought to favorably influence innate mucosal immunity but at times has also been incriminated in disease pathophysiology. Research into eosinophil biology has uncovered a number of interesting contributions by eosinophils to health and disease. However, it appears that not all eosinophils from all species are created equal. It remains unclear, for example, exactly how having eosinophils benefits the human host when helminth infections in the developed world have become scarce. This review focuses on our current state of knowledge as it relates to human eosinophils. When information is lacking, we discuss lessons learned from mouse studies that may or may not directly apply to human biology and disease. It is an exciting time to be an "eosinophilosopher" because the use of biologic agents that selectively target eosinophils provides an unprecedented opportunity to define the contribution of this cell to eosinophil-associated human diseases.
- Published
- 2020
- Full Text
- View/download PDF
46. Fibrinogen Is a Specific Trigger for Cytolytic Eosinophil Degranulation.
- Author
-
Coden ME, Loffredo LF, Walker MT, Jeong BM, Nam K, Bochner BS, Abdala-Valencia H, and Berdnikovs S
- Subjects
- Animals, CD11b Antigen metabolism, Cell Adhesion, Cell Death, Cell Degranulation, Cells, Cultured, Cytotoxicity, Immunologic, Eosinophil Major Basic Protein metabolism, Humans, Inflammation immunology, Interleukin-5 metabolism, Mice, Mice, Inbred BALB C, Microscopy, Electron, Transmission, Secretory Vesicles metabolism, Eosinophils immunology, Fibrinogen metabolism, Inflammation metabolism
- Abstract
In inflamed human tissues, we often find intact eosinophilic granules, but not eosinophils themselves. Eosinophils, tissue-dwelling granulocytes with several homeostatic roles, have a surprising association with fibrinogen and tissue remodeling. Fibrinogen is a complex glycoprotein with regulatory roles in hemostasis, tumor development, wound healing, and atherogenesis. Despite its significance, the functional link between eosinophils and fibrinogen is not understood. We tested IL-5-primed mouse bone marrow-derived and human blood-sorted eosinophil activity against FITC-linked fibrinogen substrates. The interactions between these scaffolds and adhering eosinophils were quantified using three-dimensional laser spectral, confocal, and transmission electron microscopy. Eosinophils were labeled with major basic protein (MBP) Ab to visualize granules and assessed by flow cytometry. Both mouse and human eosinophils showed firm adhesion and degraded up to 27 ± 3.1% of the substrate area. This co-occurred with active MBP-positive granule release and the expression of integrin CD11b. Mass spectrometry analysis of fibrinogen proteolytic reactions detected the presence of eosinophil peroxidase, MBP, and fibrin α-, β-, and γ-chains. Eosinophil activity was adhesion dependent, as a blocking Ab against CD11b significantly reduced adhesion, degranulation, and fibrinogenolysis. Although adhered, eosinophils exhibited no proteolytic activity on collagen matrices. Cytolytic degranulation was defined by loss of membrane integrity, cell death, and presence of cell-free granules. From transmission electron microscopy images, we observed only fibrinogen-exposed eosinophils undergoing this process. To our knowledge, this is the first report to show that fibrinogen is a specific trigger for cytolytic eosinophil degranulation with implications in human disease., (Copyright © 2020 by The American Association of Immunologists, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
47. Workup for eosinophilia.
- Author
-
Guo C and Bochner BS
- Subjects
- Biopsy, Eosinophilia etiology, Humans, Hypereosinophilic Syndrome etiology, Medical History Taking, Eosinophilia diagnosis, Hypereosinophilic Syndrome diagnosis
- Abstract
With automated differentials being a common part of routine blood counts, the finding of eosinophilia is a relatively frequent occurrence. The first step in elucidating the cause is to determine the absolute eosinophil count (AEC), which is calculated from multiplying the percentage of eosinophils by the total white blood cell count. Eosinophilia is defined as an AEC of >500 eosinophils/μL, whereas hypereosinophilia is defined as an AEC of ≥1500 eosinophils/μL, a separation that is useful as an initial approach to the evaluation of such patients. Peripheral blood eosinophilia is most commonly secondary to allergies but can also be caused by certain infections, medication reactions, autoimmune diseases, or other conditions. However, hypereosinophilia is rarely, if ever, explained by allergy alone and should always prompt a further workup. A meticulous approach to exploring key aspects of the medical history is recommended for assessing increased AECs because it helps to narrow the list of possible etiologies, and treatment varies, depending on the underlying diagnosis. Special attention should be paid to the onset of eosinophilia and any coincident events, such as travel or the start of new medications. Another critical part of the history is a thorough attempt to identify any possible eosinophil-associated end-organ damage, although a biopsy of suspected involved areas is often necessary for confirmation. Because the causes of an elevated AEC are broad, determining the trigger or underlying disorder becomes an important intellectual riddle that can usually be solved with careful attention to history, physical examination, and appropriate laboratory work.
- Published
- 2019
- Full Text
- View/download PDF
48. Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis.
- Author
-
Youngblood BA, Brock EC, Leung J, Falahati R, Bochner BS, Rasmussen HS, Peterson K, Bebbington C, and Tomasevic N
- Subjects
- Animals, Disease Models, Animal, Enteritis immunology, Eosinophilia immunology, Eosinophilic Esophagitis drug therapy, Eosinophils immunology, Female, Gastritis immunology, Gastroenteritis, Humans, Lectins immunology, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Ovalbumin, Antibodies, Monoclonal pharmacology, Antigens, CD immunology, Antigens, Differentiation, B-Lymphocyte immunology, Enteritis drug therapy, Eosinophilia drug therapy, Eosinophils drug effects, Gastritis drug therapy, Lectins drug effects, Mast Cells immunology
- Abstract
Aberrant accumulation and activation of eosinophils and potentially mast cells (MCs) contribute to the pathogenesis of eosinophilic gastrointestinal diseases (EGIDs), including eosinophilic esophagitis (EoE), gastritis (EG), and gastroenteritis (EGE). Current treatment options, such as diet restriction and corticosteroids, have limited efficacy and are often inappropriate for chronic use. One promising new approach is to deplete eosinophils and inhibit MCs with a monoclonal antibody (mAb) against sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8), an inhibitory receptor selectively expressed on MCs and eosinophils. Here, we characterize MCs and eosinophils from human EG and EoE biopsies using flow cytometry and evaluate the effects of an anti-Siglec-8 mAb using a potentially novel Siglec-8-transgenic mouse model in which EG/EGE was induced by ovalbumin sensitization and intragastric challenge. MCs and eosinophils were significantly increased and activated in human EG and EoE biopsies compared with healthy controls. Similar observations were made in EG/EGE mice. In Siglec-8-transgenic mice, anti-Siglec-8 mAb administration significantly reduced eosinophils and MCs in the stomach, small intestine, and mesenteric lymph nodes and decreased levels of inflammatory mediators. In summary, these findings suggest a role for both MCs and eosinophils in EGID pathogenesis and support the evaluation of anti-Siglec-8 as a therapeutic approach that targets both eosinophils and MCs.
- Published
- 2019
- Full Text
- View/download PDF
49. Mammalian diaphanous-related formin 1 (mDia1) coordinates mast cell migration and secretion through its actin-nucleating activity.
- Author
-
Klein O, Krier-Burris RA, Lazki-Hagenbach P, Gorzalczany Y, Mei Y, Ji P, Bochner BS, and Sagi-Eisenberg R
- Subjects
- Animals, Cell Degranulation physiology, Mice, Actin Cytoskeleton metabolism, Cell Movement physiology, Chemotaxis, Leukocyte physiology, Formins metabolism, Mast Cells metabolism
- Abstract
Background: Actin remodeling is a key regulator of mast cell (MC) migration and secretion. However, the precise mechanism underlying the coordination of these processes has remained obscure., Objective: We sought to characterize the actin rearrangements that occur during MC secretion or chemotactic migration and identify the underlying mechanism of their coordination., Methods: Using high-resolution microscopy, we analyzed the dynamics of actin rearrangements in MCs triggered to migration by IL-8 or prostaglandin E
2 or to FcεRI-stimulated secretion., Results: We show that a major feature of the actin skeleton in MCs stimulated to migration is the buildup of pericentral actin clusters that prevent cell flattening and converge the secretory granules (SGs) in the cell center. This migratory phenotype is replaced on encounter of an IgE cross-linking antigen that stimulates secretion through a secretory phenotype characterized by cell flattening, reduction of actin mesh density, ruffling of cortical actin, and mobilization of SGs. Furthermore, we show that knockdown of mammalian diaphanous-related formin 1 (mDia1) inhibits chemotactic migration and its typical actin rearrangements, whereas expression of an active mDia1 mutant recapitulates the migratory actin phenotype and enhances cell migration while inhibiting FcεRI-triggered secretion. However, mice deficient in mDia1 appear to have normal numbers of MCs in various organs at baseline., Conclusion: Our results demonstrate a unique role of actin rearrangements in clustering the SGs and inhibiting their secretion during MC migration. We identify mDia1 as a novel regulator of MC response that coordinates MC chemotaxis and secretion through its actin-nucleating activity., (Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
50. A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and -F on Immune Cells.
- Author
-
Nycholat CM, Duan S, Knuplez E, Worth C, Elich M, Yao A, O'Sullivan J, McBride R, Wei Y, Fernandes SM, Zhu Z, Schnaar RL, Bochner BS, and Paulson JC
- Subjects
- Animals, Antigens, CD metabolism, Antigens, Differentiation, B-Lymphocyte metabolism, B-Lymphocytes metabolism, CHO Cells, Cricetulus, Humans, Lectins metabolism, Liposomes chemistry, Liposomes metabolism, Mice, Molecular Conformation, Sialic Acid Binding Immunoglobulin-like Lectins, Sialic Acids chemistry, Sulfonamides chemistry, T-Lymphocytes metabolism, Antigens, Differentiation, Myelomonocytic metabolism, B-Lymphocytes drug effects, Lectins antagonists & inhibitors, Sialic Acids pharmacology, Sulfonamides pharmacology, T-Lymphocytes drug effects
- Abstract
The Siglec family of cell surface receptors have emerged as attractive targets for cell-directed therapies due to their restricted expression on immune cells, endocytic properties, and ability to modulate receptor signaling. Human Siglec-8, for instance, has been identified as a therapeutic target for the treatment of eosinophil and mast cell disorders. A promising strategy to target Siglecs involves the use of liposomal nanoparticles with a multivalent display of Siglec ligands. A key challenge for this approach is the identification of a high affinity ligand for the target Siglec. Here, we report the development of a ligand of Siglec-8 and its closest murine functional orthologue Siglec-F that is capable of targeting liposomes to cells expressing Siglec-8 or -F. A glycan microarray library of synthetic 9- N -sulfonyl sialoside analogues was screened to identify potential lead compounds. The best ligand, 9- N -(2-naphthyl-sulfonyl)-Neu5Acα2-3-[6- O -sulfo]-Galβ1-4GlcNAc (6'- O -sulfo
NSA Neu5Ac) combined the lead 2-naphthyl sulfonyl C-9 substituent with the preferred sulfated scaffold. The ligand 6'- O -sulfoNSA Neu5Ac was conjugated to lipids for display on liposomes to evaluate targeted delivery to cells. Targeted liposomes showed strong in vitro binding/uptake and selectivity to cells expressing Siglec-8 or -F and, when administered to mice, exhibit in vivo targeting to Siglec-F+ eosinophils.- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.